Literature DB >> 21622126

Asthma treatment through the beta receptor: lessons from animal models.

Erik P Riesenfeld1, Charles G Irvin.   

Abstract

Asthma is a significant health problem worldwide with a prevalence that continues to rise and for which there is no cure. Animal models have been used for decades to investigate the cause and cures of asthma, and while they do not always mimic many of the facets of this syndrome, mechanistic animal studies are still nevertheless very useful. Animal studies with beta-agonists suggest much broader and perhaps more important roles for beta-agonists since beta-agonists reduce aspects of inflammation and may affect structural remodeling. Studies using enantiomers of beta-agonists provide a confusing picture of the degree and mechanism of the deleterious effects of racemic mixtures and/or the S-enantiomer or other classes of beta-agonists. Neural mechanisms are implicated. The future holds a promise of even more insight into the mechanisms of the acute and chronic role of the beta-adrenoceptor, asthma therapeutics, in particular, beta-agonists that will lead to a better understanding of the pathogenesis and treatment of asthma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622126      PMCID: PMC8669294          DOI: 10.2741/e323

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  65 in total

1.  The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.

Authors:  Nicola A Hanania; Supria Singh; Rami El-Wali; Michael Flashner; Amie E Franklin; William J Garner; Burton F Dickey; Sergio Parra; Stephen Ruoss; Felix Shardonofsky; Brian J O'Connor; Clive Page; Richard A Bond
Journal:  Pulm Pharmacol Ther       Date:  2007-07-17       Impact factor: 3.410

Review 2.  Bronchial asthma: lessons from murine models.

Authors:  G J Gleich; H Kita
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

3.  (R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma: con].

Authors:  Bill T Ameredes; William J Calhoun
Journal:  Am J Respir Crit Care Med       Date:  2006-11-01       Impact factor: 21.405

4.  Genetic variability in pulmonary physiological, cellular, and antibody responses to antigen in mice.

Authors:  J P Brewer; A B Kisselgof; T R Martin
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

Review 5.  The mouse trap.

Authors:  C G Persson; J S Erjefält; M Korsgren; F Sundler
Journal:  Trends Pharmacol Sci       Date:  1997-12       Impact factor: 14.819

6.  Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.

Authors:  A Kamachi; M Munakata; Y Nasuhara; M Nishimura; Y Ohtsuka; M Amishima; T Takahashi; Y Homma; Y Kawakami
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

7.  Enhancement of airway reactivity to histamine by isoprenaline and related beta-adrenoceptor agonists in the guinea-pig.

Authors:  B C Galland; J G Blackman
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

8.  Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model.

Authors:  Long P Nguyen; Ozozoma Omoluabi; Sergio Parra; Joanna M Frieske; Cecilia Clement; Zoulikha Ammar-Aouchiche; Samuel B Ho; Camille Ehre; Mehmet Kesimer; Brian J Knoll; Michael J Tuvim; Burton F Dickey; Richard A Bond
Journal:  Am J Respir Cell Mol Biol       Date:  2007-12-20       Impact factor: 6.914

Review 9.  Animal models of asthma.

Authors:  G R Zosky; P D Sly
Journal:  Clin Exp Allergy       Date:  2007-07       Impact factor: 5.018

10.  Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness.

Authors:  Hiroyuki Tashimo; Naomi Yamashita; Hirofumi Ishida; Hiroyuki Nagase; Tetsuya Adachi; Junichi Nakano; Koichi Yamamura; Tomoko Yano; Hisanao Yoshihara; Ken Ohta
Journal:  Allergol Int       Date:  2007-07-01       Impact factor: 5.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.